Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:119943514" >
Effectiveness of ad...
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
-
Van den Bosch, F (författare)
-
Manger, B (författare)
-
Goupille, P (författare)
-
visa fler...
-
McHugh, N (författare)
-
Rodevand, E (författare)
-
Holck, P (författare)
-
- van Vollenhoven, RF (författare)
- Karolinska Institutet
-
Leirisalo-Repo, M (författare)
-
FitzGerald, O (författare)
-
Kron, M (författare)
-
Frank, M (författare)
-
Kary, S (författare)
-
Kupper, H (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009-10-07
- 2010
- Engelska.
-
Ingår i: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 69:2, s. 394-399
- Relaterad länk:
-
https://ard.bmj.com/...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- To evaluate the effectiveness of adalimumab in patients with psoriatic arthritis (PsA) and identify predictors of good clinical response for joint and skin lesions.Methods:Patients received adalimumab 40 mg every other week in addition to standard therapy in this prospective, 12-week, open-label, uncontrolled study. Four definitions of good clinical response were used: ⩾50% improvement in American College of Rheumatology response criteria (ACR50), good response according to European League Against Rheumatism (EULAR) guidelines, a ⩾3-grade improvement in Physician Global Assessment of psoriasis (PGA) and a ⩾50% improvement in the Nail Psoriasis Severity Index (NAPSI). Response predictors were determined by logistic regression with backward elimination (selection level was 5%).Results:Of 442 patients, 94% completed 12 weeks of treatment. At week 12, 74%, 51% and 32% of the patients had achieved ACR20, 50 and 70, respectively; 87% and 61% experienced moderate and good responses according to EULAR criteria, respectively. The percentage of patients with PGA results of “clear/almost clear” increased from 34% (baseline) to 68%. The mean NAPSI score was reduced by 44%. No new safety signals were detected. A lower Health Assessment Questionnaire Disability Index (HAQ-DI) score, greater pain assessment, male sex and absence of systemic glucocorticoid therapy were strongly associated with achievement of ACR50 and good response according to EULAR criteria. In addition, greater C-reactive protein concentration and polyarthritis predicted ACR50, and non-involvement of large joints predicted a good response according to EULAR criteria.Conclusions:Adalimumab was effective in patients with PsA. Lower impairment of physical function, greater pain, male sex and no systemic treatment with glucocorticoids were factors that increased the chance of achieving a good clinical response.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Van den Bosch, F
-
Manger, B
-
Goupille, P
-
McHugh, N
-
Rodevand, E
-
Holck, P
-
visa fler...
-
van Vollenhoven, ...
-
Leirisalo-Repo, ...
-
FitzGerald, O
-
Kron, M
-
Frank, M
-
Kary, S
-
Kupper, H
-
visa färre...
- Artiklar i publikationen
-
Annals of the rh ...
- Av lärosätet
-
Karolinska Institutet